As of June 12, 2018 our Privacy Policy has been updated. For individuals in the European Union, CIL uses cookies on this website. Please review the new privacy statement to see how. By continuing to use this website you agree to us using cookies in accordance with our privacy statement. Click here for the new privacy statement..OK

Deuterated Reagents for Pharmaceuticals

Stable Isotope-Labeled Synthetic Intermediates

Deuterated Reagents for Pharmaceutical and Synthetic Applications

  • Deuterated Reagents for Pharmaceutical and Synthetic Applications

Stable Isotope-Labeled Synthetic Intermediates

In recent years, some pharmaceutical companies have begun to investigate deuteration of molecules that may provide advantages over their existing nondeuterated counterparts. In addition, increasing research into the potential medical advantages of new deuterated drugs is also occurring. 

The potential advantages of deuterated pharmaceuticals includes:

Improved metabolic profile. The improved metabolic profile may potentially reduce or eliminate unwanted side effects or undesirable drug interactions.

Improved oral bioavailability. Deuteration in some compounds has reduced the presystemic metabolism that occurs in the digestive track, allowing more of the unmetabolized drug to reach its target.

Increased half-life. Deuterated compounds can have a slower pharmacokinetic effect, extending the absorption and distribution in the body. This may decrease the number of doses a patient may require in a certain time period compared to its nondeuterated counterpart.

Catalog No. Description
DLM-112  Acetaldehyde-d (D, 99%) 
DLM-12RG*  Acetic acid-d4 (D, 99%)
DLM-1556 Acetic acid-d (D, 98%)
DLM-1162 Acetic anhydride-d6 (D, 98%) 
DLM-9RG* Acetone-d6 (D, 99.5%) 
DLM-247 Acetyl chloride-d3 (D, 98%) 
DLM-855 Acrylic-2,3,3,-d3 acid (+ 0.1% 4-methoxyphenol) (D, 98%)  (<5% H2O)
Ammonium deuteroxide-d(D, 99%) (~25% sol. in D2O)
DLM-862 Aniline-ring-d(D, 98%)
DLM-1RG*  Benzene-d6 (D, 99%)
DLM-494  Biphenyl- d10  (D, 98%) 
DLM-1315  Borane-d3, (D, 98%) (1 molar in THF) (+0.005M NaBD4) 
DLM-4747 Borane-d3 methylsulfide complex (D, 98%) (contains <10% additional dimethylsulfide)
DLM-398  Bromobenzene-d5 (D, 99%)
DLM-874 Bromoethane-d5 (D, 98%) 
DLM-181  1,4-Butanediol-2,2,3,3-d4 (D, 98%)
DLM-1664 tert-Butanol-d10 (D, 98%) 
DLM-10515 tert-Butyl-acetate-d9 (D, 98%) 
DLM-1116  tert-Butyl chloride-d9 (D, 98%) 
DLM-263  Chlorobenzene-d5 (D, 99%) 
DLM-337 Chloromethane-d3 (D, 99%)
DLM-7RG* Chloroform-d (D, 99.7%)
DLM-1560  Cyclohexanone-d10 (D, 98%)
DLM-2781 Cyclopentyl bromide-d9 (D, 98%)
DLM-1003DR Deuterium (D, 99.96) <400 ppm HD
DLM-408DR Deuterium (D, 99.8%) (D2, 99.6% + HD, 0.4%)
DLM-458DR Deuterium chloride (D, 99%)
DLM-3DR  Deuterium chloride (D, 99.5%) DCl 35% w/w solution in D2
DLM-2  Deuterium chloride (D, 99.5%) DCl 20% w/w solution in D2O
DLM-4DR Deuterium oxide (D, 99.9%)
DLM-4DR-99.8 Deuterium oxide (D, 99.8%)
DLM-195  1,2-Dibromoethane-d4 (D, 99%)
DLM-6020-1.2  1,2-Dibromopropane-d6 (D, 98%)
DLM-158 1,2-Dichlorobenzene-d4 (D, 99%)
Dimethyl-d6-amine:HCI (D,98%)
DLM-3903 Dimethyl carbonate-d6 (D, 99%)
DLM-196 Dimethyl sulfate-d6 (D, 98%) 
DLM-10RG* Dimethyl sulfoxide-d6 (D, 99.9%)
DLM-25 N,N-Dimethylformamide-d7 (D, 99.5%)
DLM-1670  N,N Dimethylformamide (formyl-D, 98-99%)
DLM-31 Ethanol-d6 (D, 99%) anhydrous
DLM-31RG* Ethanol-d6 (D, 99%) 5-6% D2O
DLM-16 Ethanol-OD (D, 99%) <6% D2O
DLM-9660 N-Ethylaniline-d10 (D, 98%)
DLM-9626 N-Ethyl-d5-aniline (D, 98%)
DLM-347 Ethylene-d4 (D, 98%)
DLM-805 Formaldehyde-d2 (D, 98%) (~20% w/w in D2O)
DLM-286 Formic acid-d2 (D, 98%) (<5% D2O)
DLM-743 Formic acid (formyl-D, 98%) (<5% H2O)
DLM-423 n-Heptane-d16 (D, 98%)
DLM-1023 Iodoethane-1,1-d2 (D, 98%) + copper wire
DLM-1024 Iodoethane-2,2,2-d3 (D, 98%) + copper wire
DLM-272 Iodoethane-d5 (D, 99%) + copper wire
DLM-44 Isopropanol-d8 (D, 99%)
DLM-6201 a-Ketoglutaric acid-3,3,4,4-d(D, 98%) CP 90
DLM-1945  bis(2-Chloroethoxy)-d8-methane (D, 98%) 
DLM-1981 Methanesulfonic acid-d4 (D, 97-98%)
DLM-24RG* Methanol-d4 (D, 99.5%)
DLM-15 Methanol-OD (D, 99%)
Methylboronic acid (methyl-D3, 98%) > 90% CP
DLM-651 Methyl formate (formyl-D, 99%)
DLM-362 Methyl iodide-d3 (D, 99.5%) + copper wire 
DLM-9707 Methyl-d3 methanesulfonate (D, 98%)
DLM-1500DR Methyl-d3-amine (D, 98%)
DLM-289 Methyl-d3-amine·HCl (D, 98%)
DLM-23RG* Methylene chloride-d2 (D,99.8%)
DLM-3484  Morpholine-2,2,3,3,5,5,6,6-d8  (D, 98%)
DLM-295 2-Nitrophenol-ring-d4 (D, 98%)
DLM-296 4-Nitrophenol-ring-d4  (D,98%)
DLM-619 Octanoic acid-d15 (D, 98%)
DLM-300 Paraformaldehyde-d2 (D, 99%)
DLM-370 Phenol-d6 (D, 98%)
DLM-788 Phthalic anhydride-d4 (D, 98%)
DLM-9813 Pivalic acid-trimethyl-d9, (D, 98%)
DLM-9662 Pyrrolidine-2,2,3,3,4,4,5,5-d8 (D, 98%)
DLM-3078DR N-Propanol-d7 (D, 98%)
DLM-226 Sodium borodeuteride-d4 (D, 99%) CP 90-95%
DLM-45DR Sodium deuteroxide (D, 99.5%) 40% in D2O
DLM-1361 Sodium formate (D, 98%)
DLM-8206 Sodium 2,2-dimethyl-2silapentane-5-sulfonate-d6 (DSS) (D, 98%)
DLM-33DR Sulfuric acid-d2 (D, 99%) 96-98% in D2O
DLM-36 Tetrahydrofuran-d8 (D, 99.5%)
DLM-2729 Tetramethylsilane-d12 (D, 98%)
DLM-5RG* Toluene-d(D, 99.5%)
Trifluoroacetic acid-d (D. 98%)

*Reagent grade
CP = chemical purity

Frequently Asked Questions 

What do I do if I need multiple vials or carboys when returning D2O for the D2O Recovery Program?

If you have more than ~16 L you may require multiple carboys, please just ask. 

When returning D2O for the D2O Recovery Program should I fill the carboy to the top?

No! Fill the bulk carboy container ~80% full. Most are shipped by FedEx Air, and if full, the carboy is likely to expand and possibly rupture the container.



Falb, E.; Ulanenko, K.; Tor, A.; et al. 2017. A highly efficient Suzuki-Miyaura methylation of pyridines leading to the drug pirfenidone and its CD3 version (SD-560). Green Chemistry, 21. Read article

Pepper Hamilton LLP. 2017. Deuterated drugs are new chemical entities. JDSUPRA® Read more

Mullard, A. 2016. Deuterated drugs draw heavier backing. Nat Rev Drug Discov, 15(4), 219-221PMID: 27032821

2015. Drugs that live long will prosper. The EconomistScience & Technology, Sept. 5 edition. Read article

Tung, R. 2010. The development of deuterium-containing drugs. Innovations Pharm Technol, 32(32), 24-28. Read article


Tasha Agreste

Tasha Agreste

Deuterated Reagents & Intermediates Product Manager, China Sales – Research Products

Tasha Agreste currently holds the position of Deuterated Reagents and Intermediates Product Manager, where she focuses her time working with companies on their stable isotope-labeled product needs for synthetic applications, including the manufacturing of APIs.

"CIL would like to congratulate Teva for their continuous groundbreaking work in the development of deuterated pharmaceuticals. In April 2017, Teva received approval by the US Food and Drug Administration (FDA) for the first deuterated drug product, deutetrabenazine tablets. We are extremely proud to be working with Teva and their partners in this novel area, providing high-quality deuterated reagents and intermediates, from research and development through commercialization."
CIL's Deuterated Reagents Team